Thus, because of high selectivity, excellent in vitro and in vivo activity compounds 66 and 32 can serve as a novel lead for further pre-clinical and clinical trials, but its cytotoxcity profile needs to be monitored during its evaluation. Also compound 64 which showed excellent in vitro, in vivo activity and high selectivity index against the T. b. rhodesiense merits further SAR optimization in order to synthesized newer lead compounds with reduced cytotoxicity compared to pentamidine. 